Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube

Author:

Bury Didi12ORCID,Wolfs Tom F W134ORCID,ter Heine Rob2ORCID,Muilwijk Eline W5ORCID,van der Elst Kim C M6ORCID,Tissing Wim J E17ORCID,Brüggemann Roger J M128ORCID

Affiliation:

1. Princess Maxima Center for Pediatric Oncology , Utrecht , The Netherlands

2. Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Medical Innovation , Nijmegen , The Netherlands

3. Department of Infectious Diseases, Wilhelmina Children’s Hospital/University Medical Center Utrecht , Utrecht , The Netherlands

4. Department of Infectious Diseases, Princess Maxima Center for Pediatric Oncology , Utrecht , The Netherlands

5. Department of Pharmacy, Princess Maxima Center for Pediatric Oncology , Utrecht , The Netherlands

6. Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University , Utrecht , The Netherlands

7. Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen , Groningen , The Netherlands

8. Center of Expertise in Mycology Radboudumc/CWZ , Nijmegen , The Netherlands

Abstract

Abstract Objectives To study the isavuconazole pharmacokinetics in a real-life paediatric cohort and confirm whether the isavuconazole exposures are within the adult exposure range. Furthermore, we are the first to describe unbound isavuconazole pharmacokinetics. Methods In this prospective, observational study, the isavuconazole dosing regimen was as follows (IV/oral/nasogastric tube): 5.4 mg/kg isavuconazole (maximum 200 mg/dose) three times daily on Days 1 and 2, followed by 5.4 mg/kg isavuconazole (maximum 200 mg/dose) once daily. At least one pharmacokinetic curve was assessed. Non-linear mixed effects modelling was used for analysis. Monte Carlo simulations were performed with the above mentioned maintenance dose for IV administrations and a weight band dosing regimen for oral/nasogastric tube administrations: I) <18 kg (100 mg daily); II) 18–37 kg (150 mg daily); III)>37 kg (200 mg daily). Results Seventeen paediatric patients with a median age of 9 years (range 1–17) and median weight of 26.0 kg (range 8.4–78.5) were evaluated. A two-compartment model describing linear pharmacokinetics of the unbound concentrations and saturable protein binding fitted the isavuconazole concentrations best. The absolute bioavailability of isavuconazole was 41.0% (95% CI: 32.4%–50.8%). The median (IQR) simulated exposures (AUC0–24h, SS) of the total isavuconazole concentrations after IV and oral/nasogastric tube administration were 87.7 mg·h/L (70.5–105.1) and 50.3 mg·h/L (39.0–62.4), respectively. The unbound isavuconazole fraction (unbound/total) ranged from 0.5% to 2.3%. Conclusions This study revealed low bioavailability after nasogastric tube administration with opened capsules. Isavuconazole exposures were in the expected range following IV administration. Total and unbound isavuconazole pharmacokinetics were reported with a 5-fold range in the unbound fraction.

Funder

Pediatric Oncology Foundation Groningen

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3